Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 1.00 |
| ▸ | PGR | P06401 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.73 |
| ▸ | AR | P10275 | 2/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | IL5 | P05113 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | MMP9 | P14780 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | THPO | P40225 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desonide SCHEMBL3631 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL13026139 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL18600318 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL4295093 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL5481974 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL12235707 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL9848320 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL1650014 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL21570018 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL20535949 | 0.99 | NR3C1 (0.98) | NR3C1PGRCYP3A4HSD17B10HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-117054556-A | Method for detecting external release rate of budesonide emulsion | 江苏知原药业股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-114324649-A | Method for detecting impurities in desonide emulsifiable paste | 江苏知原药业股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| CN-101896161-A | Solid formulations of crystalline compounds | PURDUE RESEARCH FOUNDATION | 2010-11-24 | — | — | CN | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100222311-A1 | SOLID FORMULATIONS OF CRYSTALLINE COMPOUNDS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | PPP3R1, CHP1, NR3C1 | NR3C1 3/4885PGR 402/4885CYP3A4 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.